Anastrozole, Exemestane
ATC CODE
- L02BG
INDICATIONS AND NEMLC RECOMMENDATIONS
INDICATIONS AND NEMLC RECOMMENDATIONS 1
INDICATION
- Adjuvant breast cancer.
RECOMMENDATION
- Approved
for use in women with confirmed intolerance to tamoxifen, i.e. thrombo-embolic disease or endometrial hyperplasia (proven on ultrasound).
Choice of aromatase inhibitor will depend on best tender price.
REVIEW INDICATORS
- Publication of the ongoing Secondary Adjuvant Long term Study with Arimidex (SALSA) study and ATAC .
- Long term data BIG 1-98.
- TEAM data late in 2008.
- Price parity with tamoxifen.
DATE RATIFIED
- 27 November 2008
INDICATIONS AND NEMLC RECOMMENDATIONS 2
INDICATION
- Metastatic breast cancer.
RECOMMENDATION
- Approved
for use as second-line therapy after tamoxifen in advanced breast cancer in postmenopausal women who do not have visceral metastases.
Choice of aromatase inhibitor will depend on best tender price.
REVIEW INDICATORS
- Further developments regarding tamoxifen pharmacogenetics.
DATE RATIFIED
- September 2010